AtaiBeckley (ATAI) Cash from Investing Activities (2020 - 2026)
AtaiBeckley's (ATAI) quarterly Cash from Investing Activities came in at -$21.7 million in Q1 2026, down 96.6% year-on-year from -$636.0 million in Q1 2025, and down 96.6% quarter-over-quarter from -$11.0 million in Q1 2025.
AtaiBeckley (ATAI) Cash from Investing Activities (2020 - 2026) Analysis & Trends
AtaiBeckley (ATAI) has 6 years of Cash from Investing Activities data on file, last reported at -$67.6 million in Q3 2025.
- For the quarter ending Q3 2025, Cash from Investing Activities fell 371.95% year-over-year to -$67.6 million; the trailing twelve-month figure through Sep 2025 stood at -$62.2 million (down 220.15% YoY), and the FY2024 full-year result was $59.2 million, up 211.03% from the prior year.
- Cash from Investing Activities eased to -$21.7 million in Q1 2026 per ATAI's latest filing, from -$11.0 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$11.0 million in Q1 2025 and bottomed at -$21.7 million in Q1 2026.
- A 5-year average of -$12.2 million and a median of -$823000.0 in 2023 frame the typical range for Cash from Investing Activities.
- Peak annual rise in Cash from Investing Activities reached 10857.33% in 2022, while the deepest fall reached 5670.92% in 2022.
- Tracing ATAI's Cash from Investing Activities over 5 years: stood at -$48.6 million in 2021, then jumped by 264.6% to $80.1 million in 2022, then tumbled by 101.03% to -$823000.0 in 2023, then surged by 897.08% to $6.6 million in 2024, then sank by 1129.77% to -$67.6 million in 2025.
- Business Quant data shows ATAI's Cash from Investing Activities at -$67.6 million in Q3 2025, $9.8 million in Q2 2025, and -$11.0 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | AtaiBeckley | 1.56 Bn | 1.56 Bn | - | -67.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.65 Mn |
| Mar 31, 2026 | -21.65 Mn |
| Sep 30, 2025 | -67.55 Mn |
| Sep 30, 2025 | -67.55 Mn |
| Jun 30, 2025 | 9.78 Mn |
| Jun 30, 2025 | 9.78 Mn |
| Mar 31, 2025 | -11.01 Mn |
| Mar 31, 2025 | -11.01 Mn |
| Mar 31, 2025 | -11.01 Mn |
| Mar 31, 2025 | -11.01 Mn |
| Dec 31, 2024 | 6.56 Mn |
| Dec 31, 2024 | 6.56 Mn |
| Sep 30, 2024 | 24.84 Mn |
| Sep 30, 2024 | 24.84 Mn |
| Jun 30, 2024 | 16.30 Mn |
| Jun 30, 2024 | 16.30 Mn |
| Mar 31, 2024 | 11.47 Mn |
| Mar 31, 2024 | 11.47 Mn |
| Dec 31, 2023 | -823,000.00 |
| Dec 31, 2023 | -823,000.00 |